GTBP
Price:
$3.06
Market Cap:
$6.84M
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies fo...[Read more]
Industry
Biotechnology
IPO Date
2018-03-27
Stock Exchange
NASDAQ
Ticker
GTBP
According to GT Biopharma, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 419.05K. This represents a change of -78.00% compared to the average of 1.90M of the last 4 quarters.
The mean historical Enterprise Value of GT Biopharma, Inc. over the last ten years is 361.57M. The current 419.05K Enterprise Value has changed -88.41% with respect to the historical average. Over the past ten years (40 quarters), GTBP's Enterprise Value was at its highest in in the June 2021 quarter at 15.55B. The Enterprise Value was at its lowest in in the June 2024 quarter at -4695199.70.
Average
361.57M
Median
62.40M
Minimum
9.28M
Maximum
2.24B
Discovering the peaks and valleys of GT Biopharma, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.61%
Maximum Annual Enterprise Value = 2.24B
Minimum Annual Increase = -98.18%
Minimum Annual Enterprise Value = 9.28M
Year | Enterprise Value | Change |
---|---|---|
2023 | 9.28M | -59.15% |
2022 | 22.73M | -70.46% |
2021 | 76.94M | 46.14% |
2020 | 52.65M | 192.64% |
2019 | 17.99M | -98.18% |
2018 | 990.43M | -55.75% |
2017 | 2.24B | 2.61% |
2016 | 82.73M | 24.67% |
2015 | 66.36M | 13.55% |
2014 | 58.44M | 3.12% |
The current Enterprise Value of GT Biopharma, Inc. (GTBP) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
36.32M
5-year avg
35.92M
10-year avg
361.57M
GT Biopharma, Inc.’s Enterprise Value is greater than Allarity Therapeutics, Inc. (-11495345.00), greater than NeuroBo Pharmaceuticals, Inc. (-1095056.00), less than Hillstream BioPharma, Inc. (1.48M), less than Virax Biolabs Group Limited (5.36M), greater than Quoin Pharmaceuticals, Ltd. (-162664.00), less than Panbela Therapeutics, Inc. (4.75M), less than Virpax Pharmaceuticals, Inc. (4.57M), greater than Revelation Biosciences, Inc. (-3300245.00), greater than Biodexa Pharmaceuticals Plc (-2820215.62), less than Praxis Precision Medicines, Inc. (1.22B), less than Pulmatrix, Inc. (11.57M), less than Oncorus, Inc. (42.71M), less than Akari Therapeutics, Plc (17.47M), greater than Sonnet BioTherapeutics Holdings, Inc. (-907921.00), less than Landos Biopharma, Inc. (42.62M), less than Cingulate Inc. (5.36M), less than SAB Biotherapeutics, Inc. (24.24M), less than Anebulo Pharmaceuticals, Inc. (36.46M), less than Cadrenal Therapeutics, Inc. Common Stock (20.50M), less than Monopar Therapeutics Inc. (100.06M), less than Protara Therapeutics, Inc. (2.28M), less than Vaccinex, Inc. (6.56M), less than Miromatrix Medical Inc. (90.06M), greater than Surrozen, Inc. (250.67K),
Company | Enterprise Value | Market cap |
---|---|---|
-11495345.00 | $5.63M | |
-1095056.00 | $20.42M | |
1.48M | $4.17M | |
5.36M | $8.73M | |
-162664.00 | $2.95M | |
4.75M | $1.69M | |
4.57M | $4.59M | |
-3300245.00 | $3.24M | |
-2820215.62 | $2.32M | |
1.22B | $1.39B | |
11.57M | $22.35M | |
42.71M | $0 | |
17.47M | $18.72M | |
-907921.00 | $2.50M | |
42.62M | $71.68M | |
5.36M | $15.42M | |
24.24M | $28.89M | |
36.46M | $37.86M | |
20.50M | $24.86M | |
100.06M | $106.08M | |
2.28M | $49.31M | |
6.56M | $9.41M | |
90.06M | $92.95M | |
250.67K | $29.74M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like GT Biopharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like GT Biopharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is GT Biopharma, Inc.'s Enterprise Value?
What is the highest Enterprise Value for GT Biopharma, Inc. (GTBP)?
What is the 3-year average Enterprise Value for GT Biopharma, Inc. (GTBP)?
What is the 5-year average Enterprise Value for GT Biopharma, Inc. (GTBP)?
How does the current Enterprise Value for GT Biopharma, Inc. (GTBP) compare to its historical average?